Alcohol and Baclofen: what the published research says
PubMed indexes 8 records that name Alcohol and Baclofen together, either in the title or in an interaction, co-administration, or pharmacokinetic context. Each one is listed below with its study design and, where the abstract states one, the authors’ own conclusion, quoted and linked. This page reports that literature. It does not tell you whether to combine them.
Every statement below is attributed to a named, dated, linked source.
This page lists published research relevant to Alcohol and Baclofen. It deliberately does not state whether the combination is safe, whether it interacts, in which direction, at what dose, or how far apart to take them.
A study appearing here is not proof that an interaction exists. Two substances can be named together in a paper that never tested them in combination, and a source listed as background may cover only one of them.
Findings are quoted from each abstract as the authors wrote them. NutriStack has not re-analysed, pooled, or reconciled them, and they may disagree with each other.
NutriStack’s own interaction assessment for this pair is not published here. It has not completed qualified-human clinical review, so it is withheld from search. See the publication gate.
Nothing here is medical advice. Decisions about prescription medication and supplements belong with your prescriber or pharmacist, who can see your full regimen.
The research
8 studies naming Alcohol and Baclofen.
Strongest relevance first: papers naming both substances in the title, then human trials and systematic reviews.
“Our results question baclofen's utility in the long-term treatment of alcohol use disorder at both normal and high doses. While the confidence intervals indicate that marginally harmful or moderately beneficial effects of baclofen remain a possibility, the most likely effect size is slightly above placebo effects.”
The Cochrane database of systematic reviews · 2023 · PMID 36637087
Systematic ReviewHuman subjects
“Baclofen likely reduces the risk of relapse to any drinking and increases the percentage of abstinent days, mainly among detoxified participants. It does not increase the number of participants with at least one adverse event, those who dropout for any reason or due to adverse events. It probably does not reduce number of heavy drinking days and the number of drinks per drinking days. Current evidence suggests that baclofen may help people with AUD in maintaining abstinence.”
The Cochrane database of systematic reviews · 2019 · PMID 31689723
Meta-AnalysisSystematic ReviewHuman subjects
“No conclusions can be drawn about the efficacy and safety of baclofen for the management of alcohol withdrawal because we found insufficient and very low-quality evidence.”
Tijdschrift voor psychiatrie · 2019 · PMID 31512738
Meta-AnalysisSystematic ReviewHuman subjects
“The other meta-analysis did not show an effect on the primary outcome measures. AIM: To clarify the clinical relevance of the effect of baclofen on alcohol use in patients with a disorder in the use of alcohol, in the light of the positive and the negative meta-analysis. METHOD: A systematic literature search using Medline, Embase and PsycINFO (Prisma guideline). RESULTS: We found 16 randomized controlled trials in which the effect of baclofen was studied.”
The Cochrane database of systematic reviews · 2018 · PMID 30484285
Meta-AnalysisSystematic ReviewHuman subjects
“None of the primary or secondary outcomes of the review showed evidence of a difference between baclofen and placebo. The high heterogeneity among primary studies results limits the interpretation of the summary estimate, the identification of moderators and mediators of baclofen's effects on alcohol use remains a challenge for further research.”
The Cochrane database of systematic reviews · 2017 · PMID 28822350
Systematic ReviewHuman subjects
“No conclusions can be drawn about the efficacy and safety of baclofen for the management of alcohol withdrawal because we found insufficient and very low quality evidence.”
The Cochrane database of systematic reviews · 2013 · PMID 23450582
Systematic ReviewHuman subjects
“The evidence for recommending baclofen for AWS is insufficient. More well designed RCTs are needed to prove its efficacy and safety.”
Names both Alcohol and Baclofen in its title.
Limitations
What this evidence cannot tell you.
Search-based evidence indexes have real limits, and it is worth being explicit about them:
Selection. These records were found by searching PubMed titles and abstracts for both substance names alongside interaction and pharmacokinetic terms. Relevant work that phrases things differently, or is not indexed in PubMed, will be missing.
No effect size. The quoted conclusions are the authors’ words about their own study. We have not extracted effect direction or magnitude, and a single study’s conclusion is not a consensus.
Population mismatch. Findings in healthy volunteers, animals, or a specific patient group may not transfer to you, your dose, or your formulation.
Absence is not safety. Few published studies means the combination is under-studied, which is not the same as established as safe.
Nearby evidence
Other pairs with published research.
Pages covering Alcohol or Baclofen alongside a different substance.
NutriStack is a free iPhone app for organising a supplement routine: what you take, when, and what the published record says about it. Its exploratory interaction checker covers Alcohol, Baclofen, and several hundred other substances.
The checker is a research and organisation tool, not a clinical decision aid, and its per-pair assessments are excluded from search until they pass claim-level review.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.